Silver Book reference

Contrast Sensitivity Outcomes in the ABC Trial: A randomized trial of bevacizumab for neovascular age-related macular degeneration

1 Matching Fact

Search matching Facts:
No results to display
    • After 54 weeks of receiving bevacizumab, wet age-realted macular degeneration (AMD) patients were more likely to gain at least 6 letters of contrast sensitivity than patikents recieving standard care–35.4% versus…